Researchers Use 10-Protein Blood Panel to Improve ALS Detection
By Dr. Zubair Khalid, DVM, MS, PhD ·
A team of researchers has developed a panel of 10 proteins in the blood to improve detection of amyotrophic lateral sclerosis (ALS). The approach aims to identify the neurodegenerative disease earlier, when interventions may still be effective.
ALS is frequently diagnosed only after significant neurological damage has already occurred. By the time a patient receives a diagnosis, the disease may have caused irreversible harm. The researchers’ protein panel is designed to detect biological clues sooner and allow clinicians to track disease progression over time.
The work addresses a long-standing gap in ALS care. Patients with the condition are often misdiagnosed for months or years, delaying access to supportive treatments and clinical trials. A blood-based test could offer a faster, less invasive route to diagnosis.
Why it matters for life sciences
Early detection of neurodegenerative diseases is a major goal in biotechnology and medicine. Biomarker panels like this one could change how quickly patients receive a correct diagnosis, enabling earlier enrollment in clinical trials and more precise monitoring of disease progression. Similar approaches are being explored for Alzheimer’s, Parkinson’s, and other neurological conditions. Reliable blood tests could also reduce the need for more invasive diagnostic procedures such as spinal taps.
Source: original report